Clinical adjuncts in in vitro fertilization: a growing list

Fertil Steril. 2019 Dec;112(6):978-986. doi: 10.1016/j.fertnstert.2019.09.019. Epub 2019 Nov 5.

Abstract

A growing list of clinical adjuncts are being used during in vitro fertilization (IVF) treatment. Most of these IVF add-ons (such as growth hormone, aspirin, heparin, dehydroepiandrostenedione, testosterone, male and female antioxidants, and screening hysteroscopy) are being introduced into routine clinical practice in a hurried manner without any clear evidence of benefit in most cases. These add-ons make the IVF more complicated and increase the overall cost for the treatment, which is borne by the couples and health care providers. Our current review found no high-quality evidence to support the use of these IVF add-ons in routine practice. Large, well-designed, randomized trials must be conducted to evaluate the effectiveness and safety of these interventions. There is also a pressing need to develop an evidence-dictated mechanism for introducing newer interventions into routine clinical settings.

Keywords: Clinical add-on; IVF add-on; IVF adjuvant; clinical adjunct.

Publication types

  • Review

MeSH terms

  • Combined Modality Therapy
  • Evidence-Based Medicine
  • Female
  • Fertility / drug effects*
  • Fertility Agents / adverse effects
  • Fertility Agents / therapeutic use*
  • Fertilization in Vitro* / adverse effects
  • Humans
  • Hysteroscopy* / adverse effects
  • Infertility / diagnosis
  • Infertility / physiopathology
  • Infertility / therapy*
  • Live Birth
  • Male
  • Platelet-Rich Plasma
  • Pregnancy
  • Pregnancy Rate
  • Semen
  • Treatment Outcome

Substances

  • Fertility Agents